Algernon Pharmaceuticals Inc.
AGN
CNSX
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 35.90% | 105.57% | 93.25% | 92.52% | 59.65% |
| Total Depreciation and Amortization | -28.52% | -45.75% | -47.08% | -48.00% | -48.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 198.68% | -183.94% | -169.49% | -154.53% | -94.56% |
| Change in Net Operating Assets | 224.19% | -199.08% | -174.33% | -149.67% | -108.98% |
| Cash from Operations | 52.59% | -75.91% | -61.04% | -6.07% | 24.13% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.80% | 8,539.70% | 5,583.17% | 3,941.95% | 2,270.51% |
| Cash from Investing | -93.44% | 8,539.70% | 5,583.17% | 3,941.95% | 2,270.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -7.82% | -75.36% | -46.83% | -51.19% | -84.72% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 67.15% | 214.14% | 312.23% | 312.23% | -75.08% |
| Cash from Financing | 13.23% | -58.45% | -27.02% | -32.71% | -82.94% |
| Foreign Exchange rate Adjustments | -206.06% | 1,100.00% | 333.33% | -300.00% | 200.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -400.49% | 120.60% | 145.70% | 136.20% | 140.14% |